Finance

Roʻyxatlar
Q3 2026 daromadi • nashr etilgan • Aksiya boʻyicha daromad kutilganidan yuqori +11,45% • Daromad kutilganidan yuqori +3,01%
Natijalarini ochish
AMG:ETR
Amgen
418,15 €
-1,26%
(-5,35) 1K
5-noy, 17:35:54 (GMT+1)  ·   EUR
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
AMG tikeri uchun statistika yaratilmoqda...
Ochish
423,95 €
Yuqori
431,20 €
Past
418,15 €
Bozor kapitali
249,01 mlrd
Oʻrtacha hajm
510,00
Hajmi
671,00
52 haftalik eng yuqori
438,75 €
52 haftalik eng past
263,60 €
Xodimlar soni
32 ming
Ochish
423,95 €
Yuqori
431,20 €
Past
418,15 €
Bozor kapitali
249,01 mlrd
Oʻrtacha hajm
510,00
Hajmi
671,00
52 haftalik eng yuqori
438,75 €
52 haftalik eng past
263,60 €
Xodimlar soni
32 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
Amgen haqida
CEORobert A. Bradway
Xodimlar soni31,5 ming
Asos solingan1980
Bosh ofislarTauzand-Oks, Kaliforniya, Amerika Qo‘shma Shtatlari
SektorHealth Care
Industry-
Veb-saytamgen.com
Oxirgi hisobot
3-noy, 2026
Moliya davri
Ch.3 2026
6,45 US$ / 5,79 US$
+11,45%musbat
Taxminiy daromad (USD)
10,36 mlrd / 10,06 mlrd
+3,01%musbat
Q3 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha
Oxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
dek, 2025
mar, 2026
iyn, 2026
sen, 2026
Daromad
9,87 mlrd
8,62 mlrd
10,05 mlrd
10,36 mlrd
Sotilgan mahsulotning tannarxi
2,68 mlrd
2,50 mlrd
2,75 mlrd
-
Daromad narxi
2,68 mlrd
2,50 mlrd
2,75 mlrd
-
Tadqiqot va ishlanmalarga xarajatlar
2,14 mlrd
1,72 mlrd
1,87 mlrd
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
1,95 mlrd
1,60 mlrd
1,74 mlrd
-
Operatsion xarajatlar
4,18 mlrd
3,21 mlrd
3,73 mlrd
-
Jami operatsion xarajatlar
6,85 mlrd
5,70 mlrd
6,48 mlrd
-
Operatsion daromad
3,01 mlrd
2,91 mlrd
3,57 mlrd
-
Boshqa nooperatsion daromad
143,00 mln
192,00 mln
145,00 mln
-
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
1,51 mlrd
2,08 mlrd
2,77 mlrd
-
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
2,51 mlrd
2,37 mlrd
3,06 mlrd
-
Daromad soligʻi boʻyicha xarajat
181,00 mln
265,00 mln
393,00 mln
-
Amaldagi soliq stavkasi
11,96%
12,72%
14,20%
-
Boshqa operatsion xarajatlar
82,00 mln
-113,00 mln
116,00 mln
-
Sof foyda
1,33 mlrd
1,82 mlrd
2,38 mlrd
-
Sof foyda marjasi
13,51%
21,11%
23,62%
-
Har bir aksiya foydasi
5,29
5,15
6,29
6,45
Foizlar va investitsiyalardan olingan daromadlar
408,00 mln
-
-
-
Foizlarni toʻlash xarajatlari
-1,06 mlrd
-657,00 mln
-673,00 mln
-
Foizlarni toʻlash boʻyicha sof xarajatlar
-653,00 mln
-657,00 mln
-673,00 mln
-
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
4,02 mlrd
4,03 mlrd
4,69 mlrd
-
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
Kelgusi tadbirlar
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari